HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

D-Galactose

HCID 6036
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
10257-28-0
Standard SMILES
OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O
InChIKey
WQZGKKKJIJFFOK-SVZMEOIVSA-N
Molecular formula
C6H12O6
Average molar mass
180.16 g/mol
Monoisotopic mass
180.0633881

Overview

D-galactopyranose is a galactopyranose having D-configuration. It has a role as a mouse metabolite and an Escherichia coli metabolite. It is a D-galactose and a galactopyranose.

Names & identifiers

Preferred name
D-Galactose
IUPAC
(3R,4S,5R,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol
English name
D-(+)-Galactose
Molecular formula
C6H12O6
Molecular weight
180.16

Names & synonyms

D-Galactopyranosegalactopyranosegalactopyranoside(3R,4S,5R,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrolD-GalCHEBI:12936CHEBI:28061CHEBI:28260GALNSC-8102RefChem:7383GlyTouCan:G68158BT
Show more names
GALACTOSE(3R,4S,5R,6R)-6-(Hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetraolNsc8102CEREBOSEGALACTOSE, D-(+)-Glucose impurity 11Lactulose impurity B(EP)-D-glucopyranosyl)-3-O-(&beta
CHEBI:37621DTXCID601437050G68158BT200-416-459-23-47IOF6H4H77Brain sugarCerebrose

Database identifiers

CAS
10257-28-0、26566-61-0、59-23-4
PubChem CID
6036
DTXSID
DTXSID001015860
ChEMBL
CHEMBL195923、CHEMBL6067641
ChEBI

Properties

Computed structural properties

XLogP
-2.6
Topological polar surface area
110 Ų
Hydrogen bond donors
5
Hydrogen bond acceptors
6
Rotatable bonds
1
Heavy atoms
12
Formal charge
0
Complexity
151

Experimental & physicochemical properties

Chemical ClassesBiological Agents -> Monosaccharides and Derivatives
CosmeticsCosmetic ingredients (Galactose) -> CIR (Cosmetic Ingredient Review)
SpringerMaterials PropertiesChemical shift
Vapor Pressure0.00000002 [mmHg]
Physical DescriptionWhite powder; [Sigma-Aldrich MSDS]
Collision Cross Section · 4 items

142.39 Ų [M+Na]+ [CCS Type: DT; Method: stepped-field]

142.1 Ų [M+Na]+ [CCS Type: DT; Method: single field calibrated with Agilent tune mix (Agilent)]

141.9 Ų [M+Na]+ [CCS Type: DT; Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]

136 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine]

Physicochemical properties

Melting point
168 · 168-170 °C(lit.)
Boiling point

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 6 items

This chemical does not meet GHS hazard criteria for 100% (180 of 180) of all reports.

Not Classified

Aggregated GHS information provided per 180 reports by companies from 2 notifications to the ECHA C&L Inventory.

Warning

H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]

P264+P265, P280, P305+P351+P338, and P337+P317 (click each P-code to see the statement)

Hazard information

Regulatory Information · 3 items

Chemical: D-Galactose

D-Galactopyranose: Does not have an individual approval but may be used under an appropriate group standard

D-Galactose: Does not have an individual approval but may be used under an appropriate group standard

Other Safety InformationIMAP assessments - D-Galactose: Human health tier I assessment
Hazards Summary · 1 item

Teratogenicity observed in rats at 55% of the diet; [Shepard's Catalog of Teratogenic Agents] Causes changes in motor activity, decreased cellular immune response, other liver changes, inflammation, other degenerative changes to brain and coverings, multiple enzyme effects, effects on lipids (including transport), changes in both tubules and glomeruli, and depressed renal function tests in acute subcutaneous studies of mice; [RTECS] May cause irritation; [Sigma-Aldrich MSDS]

Hazard Classes and Categories · 2 items

Not Classified

Eye Irrit. 2A (100%)

Toxicology

Chemistry & industry

Pharmacology

ATC Code · 2 items

V - Various

QV - Various

Protein BindingReadily accessible data regarding the protein binding of galactose is not available.
Pharmacodynamics · 1 item

Galactose is a naturally occurring monosaccharide that forms the disaccharide lactose when combined with glucose (another monosaccharide). Subsequently, when lactose or small amounts of free galactose found in various common dairy products (and other foods) are consumed, the hydrolysis of lactose to glucose and galactose occurs and galactose is itself further metabolized to generate glucose. Such glucose is, of course, ultimately relied upon and used as the primary metabolic fuel for humans in a variety of biological reactions. Conversely, however, the ways in which galactose is commonly used in therapeutic agents generally do not rely upon such pharmacodynamics, even though they ultimately remain the most important ways in which galactose exerts or elicits useful biological actions for the human body.

Mechanism of Action · 1 item

In the development of typhoid Ty21a live oral vaccine, the use of exogenous galactose is critical. When dealing with Salmonella typhimurium, it has been shown that rough strains with incomplete lipopolysaccharide (LPS) lacking O-specific side chains are much less virulent than smooth strains with complete LPS with O-specific side chains. Salmonella typhimurium gal E mutants used to produce the vaccine are effectively avirulent and highly protective but lack the specific UDP-galactose 4-epimerase enzyme which allows for the normal synthesis of UDP-galactose from UDP-glucose. The consequence of this mutant defect is that the gal E mutants can only generate incomplete LPS without O-specific antigen side chains, which are not capable enough as the complete LPS with O-specific side chains at generating an immunologic response. When exogenous galactose is added to the vaccine medium, however, it allows the mutants to generate UDP-galactose via galactose 1-phosphate. This ultimately allows the mutants to form smooth-type LPS with O-specific side chains. Regardless, the mutant's epimerase defect ultimately results in the accumulation of such intermediary products like galactose 1-phosphate and UDP-galactose, which consequently causes lysis of the mutant cells. The resultant vaccine is subsequently effective enough to elicit an immunologic response while the bacteriolysis prevents the mutant cells from regaining virulence under conditions where smooth type LPS similar to the active parental strain is synthesized. Galactose is also an essential element to the chemical structure of the commonly used laxative solution lactulose. Lactulose itself is a synthetic disaccharide that is made in parts from lactose, galactose, and various other sugars. It is poorly absorbed from the gastrointestinal tract and no enzyme capable of hydrolysis of lactulose is present in human gastrointestinal tissue. Oral doses of lactulose subsequently arrive at the colon largely unchanged. At the colon, lactulose is finally broken down predominantly to lactic acid, and also small amounts of formic and acetic acids by the action of colonic bacteria, which results in an increase in osmotic pressure and slight acidification of the colonic contents. This action consequently causes an increase in stool water content and softens the stool for a laxative effect.

Related reactions

7 records
New reaction record
HRID 7342 reaction equation
HRID 7342As product
HRID 19437 reaction equation
HRID 19437As reactant
HRID 565147 reaction equation
HRID 565147As reactant
HRID 1288645 reaction equation
HRID 1288645As product
HRID 1597767 reaction equation
HRID 1597767As product
HRID 1739613 reaction equation
HRID 1739613As reactant
HRID 2172376 reaction equation
HRID 2172376As product

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
CHEBI:4139
EC Number
200-416-4、233-595-2
Nikkaji
J330.863D
410.8 · 410.8±45.0 °C(Predicted)
Density
1.732 · 1.732±0.06 g/cm3(Predicted)
solubility
2 O: · H2O: 100 mg/mL
form
powder
pka
12.12 · 12.12±0.70(Predicted)
Cosmetic Ingredient Review (CIR)
D-(+)-GALACTOSE (10257-28-0)
CAS DataBase Reference
10257 · 10257-28-0(CAS DataBase Reference)
FDA UNII
2 RN3Q8DNE · X2RN3Q8DNE
NCI Drug Dictionary
galactose
ATC code
4 CE01 · V04CE01
Safety Statements
24 · 24/25
WGK Germany
3 · 3
RTECS
5490000 · LW5490000
F
3 · 3
Toxicity Summary
Safe in the present practices of use and concentration. Ingredient, concentration, and use information are available in documents discoverable at https://cir-reports.cir-safety.org

Safety data

F
3
wgk
3
rtecs
LW5490000
safety_code
24/25
Biological Half-LifeReadily accessible data regarding the half-life of galactose is not available.
Metabolism/Metabolites · 1 item

The primary pathway for galactose metabolism is called the Leloir pathway, so named after Luis Federico Leloir. The initial stage of this pathway is the conversion of beta-D-galactose to alpha-D-galactose by the enzyme galactose mutarotase (GALM). The pathway then performs the conversion of alpha-D-galactose to UDP-glucose by way of three principal enzymes and their reactions: galactokinase (GALK) phosphorylates alpha-D-galactose to galactose-1-phosphate (Gal-1-P); galactose-1-phosphate uridyltransferase (GALT) transfers a UMP group from UDP-glucose to Gal-1-P to form UDP-galactose; and finally, UDP galactose-4-epimerase (GALE) interconverts UDP-galactose and UDP-glucose, which completes the pathway.

Absorption, Distribution and Excretion · 4 items

The absorption of galactose from the human jejunum was calculated to be 1.0 g per minute per 30 cm of the gut.

The primary route of elimination for galactose is hepatic.

It has been documented that galactose distributes in a volume equivalent to 40% of body weight.

In subjects with no liver disease, systemic galactose clearance was calculated to be 1.5 +/- 0.1 L/min.

Uses & manufacturing

Uses · 3 items

CIR ingredient: Galactose

Component of many oligo- and polysaccharides in pectins, gums, and mucilages; Used in determination of hepatic function; [Merck Index]

Use (kg; approx.) in Germany (2009): >25

General Manufacturing Information · 2 items

D-Galactose: ACTIVE

Galactose: ACTIVE

Applications

UsesDiagnostic aid (ultrasound contrast medium).

Upstream & downstream products

Upstream raw materials

Myricetin2-Acetamido-2-deoxy-D-galactitolL-FucoseD-glucose

Downstream products

3,4,6-Tri-O-acetyl-D-galactalD-Galactalbeta-D-Galactose pentaacetate(-)-MaackiainAllyl-α-D-galactopyranoside

Additional notes

DefinitionA SUGAR found in lactose and many polysaccharides. It is an aldohexose, isomeric with glucose.

Definitiongalactose: A simple sugar, C6H12O6,stereoisomeric with glucose, that occursnaturally as one of the productsof the enzymic digestion of milksugar (lactose) and as a constituent ofgum arabic.